UA71605C2 - Composition for treatment of psoriasis based on ethanol extract from human placenta - Google Patents
Composition for treatment of psoriasis based on ethanol extract from human placenta Download PDFInfo
- Publication number
- UA71605C2 UA71605C2 UA2001096494A UA2001096494A UA71605C2 UA 71605 C2 UA71605 C2 UA 71605C2 UA 2001096494 A UA2001096494 A UA 2001096494A UA 2001096494 A UA2001096494 A UA 2001096494A UA 71605 C2 UA71605 C2 UA 71605C2
- Authority
- UA
- Ukraine
- Prior art keywords
- treatment
- psoriasis
- composition
- water
- patients
- Prior art date
Links
- 201000004681 Psoriasis Diseases 0.000 title claims abstract description 35
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- 210000002826 placenta Anatomy 0.000 title claims abstract description 27
- 239000000469 ethanolic extract Substances 0.000 title 1
- 239000004520 water soluble gel Substances 0.000 claims abstract description 13
- 239000000284 extract Substances 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 3
- 235000021313 oleic acid Nutrition 0.000 claims description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 2
- 239000012675 alcoholic extract Substances 0.000 claims 2
- 235000021319 Palmitoleic acid Nutrition 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 150000002889 oleic acids Chemical class 0.000 claims 1
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid group Chemical group C(CCCCCCC\C=C/CCCCCC)(=O)O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000012876 topography Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 20
- 210000002615 epidermis Anatomy 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 9
- 238000012360 testing method Methods 0.000 abstract description 9
- 230000000144 pharmacologic effect Effects 0.000 abstract description 3
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 230000008929 regeneration Effects 0.000 abstract description 2
- 238000011069 regeneration method Methods 0.000 abstract description 2
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 230000036560 skin regeneration Effects 0.000 abstract description 2
- 238000009472 formulation Methods 0.000 abstract 2
- 238000003556 assay Methods 0.000 abstract 1
- 231100000024 genotoxic Toxicity 0.000 abstract 1
- 230000001738 genotoxic effect Effects 0.000 abstract 1
- 230000002110 toxicologic effect Effects 0.000 abstract 1
- 231100000027 toxicology Toxicity 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 16
- 238000000034 method Methods 0.000 description 13
- 230000002682 anti-psoriatic effect Effects 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 239000000126 substance Substances 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 9
- 239000002674 ointment Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 5
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000005059 placental tissue Anatomy 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 235000019155 vitamin A Nutrition 0.000 description 3
- 239000011719 vitamin A Substances 0.000 description 3
- 229940045997 vitamin a Drugs 0.000 description 3
- 241000700159 Rattus Species 0.000 description 2
- 210000001691 amnion Anatomy 0.000 description 2
- 229960002537 betamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229960003662 desonide Drugs 0.000 description 2
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000036732 histological change Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002803 maceration Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229940126601 medicinal product Drugs 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 230000001185 psoriatic effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000037380 skin damage Effects 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 239000000021 stimulant Substances 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000003954 umbilical cord Anatomy 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- 240000006487 Aciphylla squarrosa Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 241000145297 Vanni Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003041 laboratory chemical Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 231100000130 skin irritation / corrosion testing Toxicity 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU1999016A CU22693A1 (es) | 1999-02-22 | 1999-02-22 | Composición para el tratamiento de la psoriasis y método para su obtención |
| PCT/CU2000/000001 WO2000050047A2 (es) | 1999-02-22 | 2000-02-22 | Composicion para el tratamiento de la psoriasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA71605C2 true UA71605C2 (en) | 2004-12-15 |
Family
ID=5459199
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2001096494A UA71605C2 (en) | 1999-02-22 | 2000-02-22 | Composition for treatment of psoriasis based on ethanol extract from human placenta |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1159966B1 (de) |
| JP (1) | JP2002537342A (de) |
| CN (1) | CN1165299C (de) |
| AR (1) | AR022704A1 (de) |
| AT (1) | ATE226440T1 (de) |
| BG (1) | BG105924A (de) |
| BR (1) | BR0008394A (de) |
| CA (1) | CA2363036A1 (de) |
| CU (1) | CU22693A1 (de) |
| DE (1) | DE60000658T2 (de) |
| ES (1) | ES2187446T3 (de) |
| HK (1) | HK1043938A1 (de) |
| HU (1) | HUP0200005A3 (de) |
| RU (1) | RU2225717C2 (de) |
| UA (1) | UA71605C2 (de) |
| WO (1) | WO2000050047A2 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20040423A1 (it) * | 2004-03-04 | 2004-06-04 | Pier Mario Biava | Uso di un estratto di embrioni di ovipari e di mucosa di utero gravido o di placenta di mammiferi non umani per la preparazione di un prodotto di attivita' antipsoriasica |
| CN102688483B (zh) * | 2011-03-22 | 2015-02-18 | 王成德 | 一种治疗皮肤病的组合物、含有该组合物的制剂及其制备方法 |
| RU2599038C1 (ru) * | 2015-10-22 | 2016-10-10 | Общество с ограниченной ответственностью Медицинская Корпорация "РАНА" | Применение препарата лаеннек для лечения заболевания, связанного с нарушением иммунитета, представляющего собой хронический рецидивирующий герпес, атопический дерматит или псориаз |
| CN112168812B (zh) * | 2019-07-02 | 2022-07-08 | 瑞微（深圳）生物科技有限公司 | 棕榈油酸用于制备预防或治疗炎症性疾病的组合物的用途 |
| CN114544783B (zh) * | 2020-11-20 | 2024-01-30 | 上海交通大学医学院附属瑞金医院 | 一种预防银屑病复发的内源性代谢物组合 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1061818A1 (ru) * | 1982-07-19 | 1983-12-23 | Центральный научно-исследовательский кожно-венерологический институт | Способ лечени пустулезного псориаза |
| CN1052883C (zh) * | 1994-02-02 | 2000-05-31 | 李庆和 | 一种治疗牛皮癣的中药制剂 |
| RU94022543A (ru) * | 1994-06-10 | 1996-05-20 | АОЗТ "Научно-практический центр медикобиологических проблем" | Основа лекарственного средства и способ ее изготовления |
| AU7003096A (en) * | 1996-06-21 | 1998-01-07 | Jury Evgenievich Belyaev | Semi-finished product for producing drug bases, bases obtained using the same and variants, and drugs obtained using these bases and variants |
-
1999
- 1999-02-22 CU CU1999016A patent/CU22693A1/es unknown
-
2000
- 2000-02-21 AR ARP000100724A patent/AR022704A1/es unknown
- 2000-02-22 DE DE60000658T patent/DE60000658T2/de not_active Expired - Fee Related
- 2000-02-22 CN CNB008054363A patent/CN1165299C/zh not_active Expired - Fee Related
- 2000-02-22 ES ES00907415T patent/ES2187446T3/es not_active Expired - Lifetime
- 2000-02-22 HU HU0200005A patent/HUP0200005A3/hu unknown
- 2000-02-22 RU RU2001125918/15A patent/RU2225717C2/ru not_active IP Right Cessation
- 2000-02-22 EP EP00907415A patent/EP1159966B1/de not_active Expired - Lifetime
- 2000-02-22 CA CA002363036A patent/CA2363036A1/en not_active Abandoned
- 2000-02-22 UA UA2001096494A patent/UA71605C2/uk unknown
- 2000-02-22 WO PCT/CU2000/000001 patent/WO2000050047A2/es active IP Right Grant
- 2000-02-22 AT AT00907415T patent/ATE226440T1/de not_active IP Right Cessation
- 2000-02-22 BR BR0008394-1A patent/BR0008394A/pt not_active IP Right Cessation
- 2000-02-22 JP JP2000600658A patent/JP2002537342A/ja active Pending
-
2001
- 2001-09-20 BG BG105924A patent/BG105924A/xx unknown
-
2002
- 2002-06-05 HK HK02104260A patent/HK1043938A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| BR0008394A (pt) | 2002-11-19 |
| EP1159966A2 (de) | 2001-12-05 |
| EP1159966B1 (de) | 2002-10-23 |
| RU2225717C2 (ru) | 2004-03-20 |
| CA2363036A1 (en) | 2000-08-31 |
| HUP0200005A3 (en) | 2003-03-28 |
| DE60000658D1 (de) | 2002-11-28 |
| AR022704A1 (es) | 2002-09-04 |
| JP2002537342A (ja) | 2002-11-05 |
| CN1347324A (zh) | 2002-05-01 |
| DE60000658T2 (de) | 2003-06-26 |
| WO2000050047A3 (es) | 2000-12-21 |
| WO2000050047A2 (es) | 2000-08-31 |
| ATE226440T1 (de) | 2002-11-15 |
| BG105924A (en) | 2002-04-30 |
| ES2187446T3 (es) | 2003-06-16 |
| HUP0200005A2 (hu) | 2002-05-29 |
| CU22693A1 (es) | 2001-07-31 |
| HK1043938A1 (en) | 2002-10-04 |
| CN1165299C (zh) | 2004-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US2320479A (en) | Topical remedy | |
| CN105395467A (zh) | 一种中药组合物、美肤化妆品及其应用 | |
| CN107206047A (zh) | 治疗烧伤和青光眼、减少皮肤皱纹和促进毛发生长的包含含rgd基序的肽或其片段的组合物 | |
| CN114569515A (zh) | 一种医美术后皮肤屏障受损修复的水凝胶及其制备方法 | |
| Sagher et al. | Nikolsky sign on cervix uteri in pemphigus | |
| UA71605C2 (en) | Composition for treatment of psoriasis based on ethanol extract from human placenta | |
| Jenkins et al. | Pituitary-adrenal function tests in patients with untreated pituitary tumours | |
| JP2023145593A (ja) | アツバノリ属抽出物及びその使用 | |
| Prokopyuk et al. | Experience in clinical application of cryopreserved placental derivatives: cells, tissue, membranes, extract, and cord blood serum | |
| CN115054671A (zh) | 通脑益智的中药组合物及其制备方法和应用 | |
| Gloor et al. | Predisposing factors on the surface of the skin in persons with pityriasis versicolor | |
| CN113318069A (zh) | 一种用于治疗银屑病的抗炎外用乳膏及其制备方法 | |
| US2464240A (en) | Therapeutic material and method of obtaining the same | |
| CN110075257A (zh) | 制剂及其在制备治疗湿疹药物中的用途 | |
| CN110302228A (zh) | 一种治疗痔疮的生物药剂及其应用 | |
| Torkashvand et al. | Effectiveness of Olea Herbal Ointment on Episiotomy Wound Healing Among Primiparous Women: A Randomized Clinical Trial | |
| SHAIKH et al. | Traditional remedies for wound healing: a review | |
| Mohammed et al. | Serum Levels of Oxidative Stress Biomarkers in Patients Obsessive Compulsive Disorder in Tikrit City, Iraq. | |
| CN114886794B (zh) | 一种具有抗炎和抗氧化作用的组合物及其应用 | |
| MXPA01008529A (en) | Composition for the treatment of psoriasis | |
| DE745419C (de) | Verfahren zur Herstellung eines spezifischen Heilmittels gegen Hautekzeme | |
| Tahir et al. | Effect of Hylocereus polyrhizus Extract to VEGF and TGF-β1 Level in Acute Wound Healing of Wistar Rats | |
| RU2133615C1 (ru) | Средство для лечения неврологических заболеваний | |
| JP2024511401A (ja) | 慢性皮膚潰瘍の予防または治療方法及び漢方薬組成物の薬物製造における使用 | |
| CN1256104C (zh) | 一种治疗痔疮的膏剂 |